News

AGROSPHERES ANNOUNCES NOVEL MODALITIES PARTNERSHIP WITH BAYER

AgroSpheres’ AgriCell technology will help deliver the next generation of high-performing, environmentally safe crop protection

CHARLOTTESVILLE, VA – AgroSpheres, INC., a leader in developing the next generation of environmentally friendly crop protection products, today announced a multi-year collaboration with Bayer to create novel modalities of biologicals for use as crop protection products.

“Teaming up with a leading global partner like Bayer helps us execute a mission we are both passionate about – transforming agriculture with better and more sustainable products for growers,” said Ameer Shakeel, Founder and CTO of AgroSpheres. “This collaboration also brings us one step closer to establishing AgroSpheres as a next-generation biosciences company.”

AgroSpheres’ patented AgriCell manufacturing technology enables the production of encapsulated biomolecules with enhanced stability, field persistence and targeted delivery.

“AgroSpheres’ novel AgriCell systems are innovative technologies that will help us to explore new sustainable crop protection products,” said Rachel Rama, Head of Small Molecules for Bayer. “AgroSpheres’ cutting-edge scientific team will help us as we continue to improve innovative product offerings for our grower customers.”

Biomolecules such as peptides and nucleic acids have demonstrated great promise in the lab but have generally struggled to yield consistent results for commercial biological development. The AgriCell technology fills the missing link in delivering reliable field performance and opening new markets for high-performance biopesticides. Used with novel modalities, AgriCell technology will help deliver biopesticides that:

  • Outperform traditional biologicals
  • Are non-toxic to humans and animals
  • Are durable in the environment
  • Target specific pests
  • Help manage resistance

Read more here.

Recent News

08/11/2026

Pascal Medical Corporation Secures $3.8M to Advance ClickGel Into Pivotal Large Animal Testing

Pascal Medical Corporation has raised $3.8 million to push its ClickGel surgical sealant through pivotal large animal testing on the way to human trials. The total combines a $3 million private financing round closed in July with an $800,000 grant from Virginia Catalyst, announced by Governor Abigail Spanberger on July 30, 2026. Pascal will use

08/10/2026

Expanding visibility with wearable blood pressure monitoring: CareTaker

In higher-risk patient populations, across all points of care, a patient’s condition can deteriorate quickly between routine vital sign checks, creating critical gaps in visibility and leaving clinical deterioration undetected between rounds. Continuous clinical-grade non-invasive blood pressure (CNIBP) monitoring, combined with hemodynamic trending, helps close these gaps by providing a more complete view of patient

08/10/2026

BIO-CAT Joins the Lallemand Family

BIO-CAT is pleased to join the Lallemand family as we begin an exciting new chapter together. Effective July 31, 2026, Lallemand Inc. has completed its acquisition of BIO-CAT Enzymes & Microbials. Together, we are combining complementary expertise in enzymes, microbial technologies, fermentation, and life science innovation to create an even stronger platform for developing next-generation